Top Markets
#1 Pleasing Gold Pleasing Gold +632.35%
#2 Islamic Coin Islamic Coin +154.16%
#3 PulseChain PulseChain +52.83%
#4 BOOK OF MEME BOOK OF MEME +46.61%
#5 DogBull DogBull +36.93%
#6 Neiro Neiro +27.33%
#7 Nockchain Nockchain +22.65%
#8 ORDI ORDI +19.28%
#9 rsERG rsERG +16.70%
#10 Monad Monad +16.28%
Coin of the day
Pleasing Gold Pleasing Gold
Innstillinger
Språk
NORSK
Valuta
USD
Tema
TCR2 Therapeutics Inc. TCR2 Therapeutics Inc.

TCR2 Therapeutics Inc.

TCRR
Rangering i aksjer #27036
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on... TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on developing cutting-edge T cell receptor (TCR) therapies for cancer patients. The company's lead investigational treatment, gavo-cel, is a unique mono TCR Fusion Construct T cell (TRuC-T cell) designed to target mesothelin-positive solid tumors. This therapy is currently being evaluated in Phase I/II clinical trials for non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Furthermore, TCR2 Therapeutics has concluded preclinical development for TC-510, another TRuC-T cell specifically engineered to target mesothelin on solid tumors. They are also advancing TC-520, a CD70-targeting TRuC-T cell designed with fratricide resistance for treating renal cell carcinoma. Founded in 2015, the company, formerly known as TCR2, Inc. until its name change in November 2016, is headquartered in Cambridge, Massachusetts.
Aksjekurs
$1.48
Sist synkronisert: 2023-05-31
Markedsverdi
$35.54M
Endring (1 dag)
-5.73%
Endring (1 år)
0.00%
Land
US
Handel TCR2 Therapeutics Inc. (TCRR)

Kategori

Healthcare
Inntekter for TCR2 Therapeutics Inc. (TCRR)
Inntekter i 2026 TTM: 0
Ifølge TCR2 Therapeutics Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for TCR2 Therapeutics Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH